Clinical trial · Interventional
Fatigue Intervention Trial for Breast Cancer Survivors
A Randomized Trial to Evaluate a Family-focused Mind Body Medicine Intervention to Reduce Fatigue Among Breast Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Thirty to forty percent of breast cancer survivors suffer from persistent fatigue lingering months to years after adjuvant therapy is completed. Although researchers have developed some effective interventions (exercise or group-based holistic program) to treat fatigue, none have addressed the role of the family in the patient's long-term recovery. The investigators hypothesize that a family-focused intervention in combination with a mind-body group intervention will be more effective in reducing fatigue, improving quality of life, and enhancing family relationships for breast cancer survivors than a group intervention with an individual focus.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Group based mind body medicine intervention | Behavioral | — | UNRESOLVED |
| Group-based mind body medicine intervention + family focus | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- I
- description
- 10 week group-based mind body medicine intervention
- interventionNames
- Behavioral: Group based mind body medicine intervention
- type
- EXPERIMENTAL
- label
- II
- description
- Group-based mind body medicine intervention with a family focus
- interventionNames
- Behavioral: Group-based mind body medicine intervention + family focus
Primary outcomes (1)
- measure
- Fatigue
- timeFrame
- Change from baseline to end-of-intervention and 2 and 6 months post-intervention
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Stage I-III Breast Cancer * At least 3 months since last breast cancer treatment (excluding hormonal therapy or Herceptin). * 4 week history of persistent moderate to severe fatigue * Competent to sign informed consent * Willing to be randomized Exclusion Criteria: * Metastatic breast cancer
References
Publications (0)
Data not yet available